Alcoholic Liver Disease (ALD)
At a Glance
No biochemical markers pathognomonic for alcoholic liver disease (ALD) exist. The diagnosis has to start with evidence of alcohol abuse either from a history of documented blood alcohol levels or from response to one of the questionnaires desired to elicit a history of ongoing alcohol abuse.
What Tests Should I Request to Confirm My Clinical Dx? In addition, what follow-up tests might be useful?
Historically, gamma glutamyl transpeptidase (GGT) has been used as a screening tool for alcoholism.
Another, relatively specific marker for ALD is carbohydrate deficient transferrin (CDT).
Elevations of aspartate aminotransferase up to six times the upper limit of normal and alanine aminotransferase up to 5 times its upper limit of normal is consistent with alcohol abuse, especially with a ratio greater than 2:1. A ratio of 3:1 has a sensitivity of 90% for the diagnosis.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations
- Intranasal Oxytocin Reduces Negative Effects, Improves Cognitive Function in Schizophrenia
- Most Patients Comfortable With Clinicians Asking About Sexual Orientation
- Peer-to-Peer Depression Awareness Program May Be Beneficial
- Examining Rates of Long-term Opioid Use in Youth With Psychiatric Disorders